Dechert advised Pharnext SA, a French biopharmaceutical company pioneering a new approach to the discovery of innovative drugs based on the combination of existing drugs, in an agreement with Chinese company Tasly Pharmaceutical, a group ranked amongst China’s top ten listed pharmaceutical companies. This strategic partnership includes three parts: an investment of €20 million by Tasly in Pharnext; the development of a new pipeline of synergistic combinations through a shared platform set up via the creation of a research and development Joint-Venture (JV), and the license to the JV of Pharnext’s lead product for the Chinese market currently at Phase III.

The cross-border team advising Pharnext was led by corporate partners Alain Decombe (Paris) and Jingzhou Tao (Beijing), as well as corporate national partners Lucy Lu (Beijing), Isabelle Marguet (Paris) and Anne-Charlotte Rivière (Paris), assisted by corporate associates Xavier Leroux, Quentin Durand and Guillaume Briant (Paris).